Zobrazeno 1 - 10
of 1 473
pro vyhledávání: ''
Autor:
Charlene Rivier, Elise Rowinski, Wafa Bouleftour, Elisabeth Daguenet, Benoîte Méry, Nicolas Magné
Publikováno v:
Anticancer Research
Anticancer Research, 2021, 41 (11), pp.5355-5364. ⟨10.21873/anticanres.15348⟩
Anticancer Research, 2021, 41 (11), pp.5355-5364. ⟨10.21873/anticanres.15348⟩
International audience; Cardiotoxicity is a common side effect induced by cancer therapies, which increases the risk of long-term morbidity and mortality in cancer survivors. To date, the mechanism leading to this toxicity is still unclear, thus comp
Autor:
Denisa Rozsivalova, Jana Alahakoon, Juraj Kultan, Andrea Mullerova, Kristián Brat, Daniel Krejci, Ondrej Venclicek, Libor Havel, Martin Svaton, Martina Vasakova, Petra Smickova, Ondrej Fischer, Kristyna Hrda, Jana Skrickova, Zsuzsanna Gyorfy, Miloslav Marel, Gabriela Krakorova, P. Opálka, Michal Hrnčiarik, Jaroslav Duba, Jiri Silar, Michal Svoboda, Michal Jirousek, Petr Zuna, J. Krejčí, Lydia Zarnayova
Publikováno v:
Anticancer Research. 41:5549-5556
Background/aim LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018.
Autor:
Monika Bratová, Daniel Dolezal, Michal Hrnčiarik, Marketa Cernovska, Magda Barinova, Tana Tuzova, Milada Zemanova, Martin Svaton, Ondrej Fischer, Jana Krejčí, Helena Čoupková, Jana Skrickova, Karolina Hurdalkova, Bedrich Porzer, Leona Koubková
Publikováno v:
Anticancer Research. 41:2059-2065
Background/Aim: We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. Patients and Methods: We retrospectively analysed data for 343 pa
Autor:
Akihiro Ohmoto, Naoki Fukuda, Kazuhisa Toda, Hiroki Mitani, Naomi Hayashi, Kenji Nakano, Shunji Takahashi, Yasuyoshi Sato, Junichi Tomomatsu, Makiko Ono, Tetsuya Urasaki, Xiaofei Wang
Publikováno v:
Anticancer Research. 41:1683-1691
BACKGROUND/AIM Lenvatinib is standard therapy for radioiodine-refractory differentiated thyroid cancer (RR-DTC), although the optimal timing for starting treatment is still controversial. The aim of this study was to evaluate the prognostic impact of
Autor:
Agnieszka Kulczyńska-Przybik, Barbara Mroczko, Sara Pączek, Marta Łukaszewicz-Zając, Mariusz Gryko
Publikováno v:
Anticancer Research. 41:1421-1428
Background/aim The current study aimed to evaluate the clinical utility of the levels of the C-X-C-motif chemokine receptor-2 (CXCR-2) serum receptor in comparison to the carcinoembryonic antigen (CEA) tumor marker and - the C-reactive protein (CRP)
Autor:
Chikashi Seto, Taiki Kamijima, Akinobu Takano, Satoshi Yotsuyanagi, Shuhei Aoyama, Rie Fukuda, Hideki Asahi, Kazuyoshi Shigehara, Yoshifumi Kadono, Ryunosuke Nakagawa, Takahiro Nohara, Atsushi Mizokami, Tohru Miyagi, Kouji Izumi, Shohei Kawaguchi
Publikováno v:
Anticancer Research. 41:1599-1606
BACKGROUND/AIM To investigate the blood markers for predicting pembrolizumab efficacy in advanced urothelial carcinoma (UC). PATIENTS AND METHODS This study included 91 advanced UC patients. The relationship between prognosis and markers from periphe
Publikováno v:
Anticancer Research. 41:1593-1598
Background/aim We previously showed that an elevated postoperative serum C-reactive protein (CRP) level has a negative impact on long-term survival outcomes, regardless of the occurrence of infectious complications in colorectal cancer. However, the
Publikováno v:
Anticancer Research. 41:821-828
Background/Aim: Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressivene
Autor:
Giovanni D'Ippolito, Debora Pirillo, Erminia Di Bartolomeo, Gianluca Annunziata, Valentina Mastrofilippo, Federica Torricelli, Vincenzo Dario Mandato, Gino Ciarlini, Lorenzo Aguzzoli
Publikováno v:
Anticancer Research. 41:937-948
BACKGROUND/AIM Most women are managed by a general gynaecologist rather than being centralized in an oncogynaecology unit, resulting in different clinical management. In 2006, a hub & spoke model was introduced in the Provincial Healthcare System of
Publikováno v:
Anticancer Research. 41:811-819
Background/aim The GastroPanel® test (Biohit Oyj) is interpreted by the GastroSoft® application distinguishing eight biomarker profiles, of which five profiles have a morphological equivalent in the Updated Sydney System (USS) classification of gas